

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT LAUNCH OF PROPRIETARY PRODUCT, HETANGJIN® DAPAGLIFLOZIN TABLETS

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the launch of Hetangjin®* (和唐淨) Dapagliflozin Tablets, a proprietary product of the Group of which the Group has sales rights, was held on March 9, 2024, marking the commencement of the marketing of the product after it officially obtained the drug registration certificate (Guo Yao Zhun Zi No. H20234636) from the National Medical Products Administration (國家藥品監督管理局) of China on December 13, 2023.

Dapagliflozin Tablets are the only basic drug in the sodium-glucose cotransporter 2 (“**SGLT-2**”) inhibitor class. Dapagliflozin Tablets were approved for entry into the Chinese market in 2017, and were included as a category B drug in the basic medical insurance drug catalog in China in 2019, with annual sales in China reaching approximately RMB7 billion in 2023. As an SGLT-2 inhibitor, Dapagliflozin Tablets are a first-line medication for improving glycemic control in adult patients with type 2 diabetes. Several studies have shown that Dapagliflozin Tablets can comprehensively manage multiple risk factors for cardiac and renal diseases, and are effective in lowering glycosylated hemoglobin, reducing body weight, lowering uric acid, lowering urinary albumin-to-creatinine ratio, and lowering systolic blood pressure. This type of SGLT-2 inhibitor achieved breakthroughs in body weight reduction and the prevention and treatment of cardiovascular and renal diseases, which have considerable cross-domain value.

Hetangjin® Dapagliflozin Tablets have broken through the patent restrictions on the crystalline form in the original research, and have been launched ahead of the original schedule in accordance with relevant laws and regulations as a generic product of Dapagliflozin Tablets in China. With the launch of Hetangjin® Dapagliflozin Tablets, the Group will leverage its extensive hospital network and offline pharmacy network for marketing and sales of the product, to digitally develop a broad market for the product in an efficient manner, to maximize the effect of the product on improving the quality of life of patients with chronic diseases, and to enhance the patient accessibility of quality pharmaceutical products.

The Board is of the view that the launch of Hetangjin® Dapagliflozin Tablets is a strong evidence of the Company's patient-to-industry model, which is expected to have a positive impact on the Company's financial performance and long-term development.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
ClouDr Group Limited
Kuang Ming

*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, March 11, 2024

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*